104 research outputs found
Molecular dynamic simulation of a homogeneous bcc -> hcp transition
We have performed molecular dynamic simulations of a Martensitic bcc->hcp
transformation in a homogeneous system. The system evolves into three
Martensitic variants, sharing a common nearest neighbor vector along a bcc
direction, plus an fcc region. Nucleation occurs locally, followed by
subsequent growth. We monitor the time-dependent scattering S(q,t) during the
transformation, and find anomalous, Brillouin zone-dependent scattering similar
to that observed experimentally in a number of systems above the transformation
temperature. This scattering is shown to be related to the elastic strain
associated with the transformation, and is not directly related to the phonon
response.Comment: 11 pages plus 8 figures (GIF format); to appear in Phys. Rev.
Suppression of airway inflammation by Illicium verum and trans-anethole
_Background_
SH2 domain containing inositol-5-phosphatase (SHIP1) is an important modulator of innate
and adaptive immunity. In mice, loss of SHIP1 provokes severe ileitis resembling Crohn's
disease (CD), as a result of deregulated immune responses, altered cytokine production
and intestinal fibrosis. Recently, SHIP1 activity was shown to be correlated to the presence
of a CD-associated single nucleotide polymorphism in ATG16L1. Here, we studied SHIP1
activity and expression in an adult cohort of CD patients.
_Methods_
SHIP1 activity, protein and mRNA expression in peripheral blood mononuclear cells from
CD patients in clinical remission were determined by Malachite green assay, Western blotting
an
Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial
BACKGROUND:
Irbesartan, a long acting selective angiotensin-1 receptor inhibitor, in Marfan syndrome might reduce aortic dilatation, which is associated with dissection and rupture. We aimed to determine the effects of irbesartan on the rate of aortic dilatation in children and adults with Marfan syndrome.
METHODS:
We did a placebo-controlled, double-blind randomised trial at 22 centres in the UK. Individuals aged 6-40 years with clinically confirmed Marfan syndrome were eligible for inclusion. Study participants were all given 75 mg open label irbesartan once daily, then randomly assigned to 150 mg of irbesartan (increased to 300 mg as tolerated) or matching placebo. Aortic diameter was measured by echocardiography at baseline and then annually. All images were analysed by a core laboratory blinded to treatment allocation. The primary endpoint was the rate of aortic root dilatation. This trial is registered with ISRCTN, number ISRCTN90011794.
FINDINGS:
Between March 14, 2012, and May 1, 2015, 192 participants were recruited and randomly assigned to irbesartan (n=104) or placebo (n=88), and all were followed for up to 5 years. Median age at recruitment was 18 years (IQR 12-28), 99 (52%) were female, mean blood pressure was 110/65 mm Hg (SDs 16 and 12), and 108 (56%) were taking β blockers. Mean baseline aortic root diameter was 34·4 mm in the irbesartan group (SD 5·8) and placebo group (5·5). The mean rate of aortic root dilatation was 0·53 mm per year (95% CI 0·39 to 0·67) in the irbesartan group compared with 0·74 mm per year (0·60 to 0·89) in the placebo group, with a difference in means of -0·22 mm per year (-0·41 to -0·02, p=0·030). The rate of change in aortic Z score was also reduced by irbesartan (difference in means -0·10 per year, 95% CI -0·19 to -0·01, p=0·035). Irbesartan was well tolerated with no observed differences in rates of serious adverse events.
INTERPRETATION:
Irbesartan is associated with a reduction in the rate of aortic dilatation in children and young adults with Marfan syndrome and could reduce the incidence of aortic complications
Aquecimento global: efeitos no crescimento, no desenvolvimento e na produtividade de batata
Evaluation of the US COVID-19 Scenario Modeling Hub for informing pandemic response under uncertainty
Our ability to forecast epidemics far into the future is constrained by the many complexities of disease systems. Realistic longer-term projections may, however, be possible under well-defined scenarios that specify the future state of critical epidemic drivers. Since December 2020, the U.S. COVID-19 Scenario Modeling Hub (SMH) has convened multiple modeling teams to make months ahead projections of SARS-CoV-2 burden, totaling nearly 1.8 million national and state-level projections. Here, we find SMH performance varied widely as a function of both scenario validity and model calibration. We show scenarios remained close to reality for 22 weeks on average before the arrival of unanticipated SARS-CoV-2 variants invalidated key assumptions. An ensemble of participating models that preserved variation between models (using the linear opinion pool method) was consistently more reliable than any single model in periods of valid scenario assumptions, while projection interval coverage was near target levels. SMH projections were used to guide pandemic response, illustrating the value of collaborative hubs for longer-term scenario projections
The influence of birth date on the development of seasonal cycles in red deer hinds (Cervus elaphus)
Discovery of a novel SHIP1 agonist that promotes degradation of lipid-laden phagocytic cargo by microglia.
Here, we describe the use of artificial intelligence to identify novel agonists of the SH2-containing 5' inositol phosphatase 1 (SHIP1). One of the compounds, K306, represents the most potent agonist identified to date. We find that K306 exhibits selectivity for SHIP1 vs. the paralog enzyme SHIP2, and this activation does not require the C2 domain of SHIP1 which other known SHIP1 agonists require. Thus, K306 represents a new class of SHIP1 agonists with a novel mode of agonism. Importantly, we find that K306 can suppress induction of inflammatory cytokines and iNOS in macrophages or microglia, but not by their SHIP1-deficient counterparts. K306 also reduces TNF-α production in vivo in an LPS-induced endotoxemia assay. Finally, we show that K306 enhances phagolysosomal degradation of synaptosomes and dead neurons by microglia revealing a novel function for SHIP1 that might be exploited therapeutically in dementia
- …